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Abstract
Sequential proliferation, hypertrophy and maturation of chondrocytes are required for proper endochondral bone
development and tightly regulated by cell signaling. The canonical Wnt signaling pathway acts through b-catenin to
promote chondrocyte hypertrophy whereas PTHrP signaling inhibits it by holding chondrocytes in proliferating states. Here
we show by genetic approaches that chondrocyte hypertrophy and final maturation are two distinct developmental
processes that are differentially regulated by Wnt/b-catenin and PTHrP signaling. Wnt/b-catenin signaling regulates
initiation of chondrocyte hypertrophy by inhibiting PTHrP signaling activity, but it does not regulate PTHrP expression. In
addition, Wnt/b-catenin signaling regulates chondrocyte hypertrophy in a non-cell autonomous manner and Gdf5/Bmp
signaling may be one of the downstream pathways. Furthermore, Wnt/b-catenin signaling also controls final maturation of
hypertrophic chondrocytes, but such regulation is PTHrP signaling-independent.
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Introduction
Mammalian skeletal development is controlled by two mecha-
nisms, endochondral and intramembranous bone formation.
Endochondral ossification occurs in most parts of the body and
requires a cartilage model prior to bone formation. Cartilage is
composed of chondrocytes and in the developing long bones, these
chondrocytes are organized into zones with distinct cellular
morphologies and proliferation properties. Such organization is
essential for the proper directional growth and elongation and is
subject to tight regulation by secreted signaling molecules and
transcription factors [1–3]. Proliferating chondrocytes are located
at both ends of the cartilage and express Sox9 and Col2a1. Closer to
the middle of the cartilage, proliferating chondrocytes become
elongated and line up in columns along the longitudinal axis.
These columnar chondrocytes divide quickly and begin to express
Indian hedgehog (Ihh) and Runx2 as they exit the cell cycle to
become prehypertrophic chondrocytes. Prehypertrophic chondro-
cytes then differentiate into hypertrophic chondrocytes that no
longer express Sox9 and Col2a1, but express Col10a1 and
angiogenic factors such as vascular endothelial growth factor
(Vegf). Hypertrophic chondrocyes can be further divided into two
populations according to their differences in gene expression and
mineralization levels. Ihh and parathyroid hormone receptor 1
(Pthr1) are expressed only in prehypertrophic and early hypertro-
phic chondrocytes. The mature population of hypertrophic
chondrocytes express Osteopontin (Opn) [4] and matrix metallo-
proteinase 13 (Mmp13) that is required for invasion of blood vessels
and osteoblasts to form the trabecular bone [5]. These most
mature hypertrophic chondrocytes undergo apoptosis and are
removed eventually. In addition, calcium deposition in the
cartilage, which can be visualized by Von Kossa and Alizarin
red staining, only occurs in the extracellular matrix of the final
mature hypertrophic chondrocytes. Thus, both chondrocyte
hypertrophy and final maturation are required for endochondral
bone formation. However, it is not clear whether chondrocyte
hypertrophy and final maturation are two consecutive develop-
mental processes regulated by the same molecular pathways or
they are actually developmentally separated and differentially
regulated.
Ihh, parathyroid hormone related peptide (PTHrP), Wnts, Bone
morphogenetic proteins (Bmps) and fibroblast growth factor (Fgfs)
etc., regulate progressive chondrocyte proliferation and hypertro-
phy. PTHrP and Ihh are major regulators of chondrocyte
hypertrophy by forming a negative feedback loop [6]. Ihh activates
PTHrP expression and PTHrP then signals to proliferating
chondrocytes to inhibit Ihh expression and chondrocyte hypertro-
phy by holding chondrocytes in a proliferating state. Wnt signaling
pathways also regulate chondrocyte hypertrophy [7–10]. Among
known Wnt signaling pathways, the canonical Wnt signaling
pathway mediated by b-catenin [11] is the best understood and
has been found to promote both chondrocyte hypertrophy and
final maturation [9,10]. Wnt/b-catenin signaling acts indepen-
dently of Ihh signaling to promote chondrocyte hypertrophy [12],
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e6067but it is unknown whether Wnt/b-catenin and PTHrP signaling
pathways regulate each other to control chondrocyte hypertrophy
and maturation.
Here we have investigated the regulation of chondrocyte
hypertrophy and final maturation and the genetic relationship
between the canonical Wnt and PTHrP signaling pathways in
sequential chondrocyte differentiation. We uncovered that chon-
drocyte hypertrophy and final maturation are two distinct
processes that are differentially regulated by Wnt/b-catenin and
PTHrP signaling. Canonical Wnt signaling promotes chondrocyte
hypertrophy by antagonizing PTHrP signaling activity. However,
the final maturation of hypertrophy chondrocytes is controlled by
Wnt/b-catenin signaling independently of PTHrP signaling.
Results
Wnt signaling controls chondrocyte hypertrophy by
antagonizing PTHrP signaling
To test whether Wnt/b-catenin signaling acts through the
PTHrP pathway in regulating chondrocyte hypertrophy, we first
examined whether PTHrP expression was regulated by Wnt/b-
catenin signaling in the developing long bone cartilage. b-catenin
was removed in chondrocytes using the Col2a1-Cre mouse line
[13]. The onset of chondrocyte hypertrophy at 12.5 days post
coitum (dpc) were not altered [9]. However, continued initiation of
chondrocyte hypertrophy by the remaining proliferating chondro-
cytes was slower in the Catnb
c/c;Col2a1-Cre mouse embryos [9].
PTHrP expression in the b-catenin deficient cartilage was similar to
that in the control, but weaker at 14.5dpc (Fig. 1A). This is likely
secondary to weakened Ihh expression in the cartilage of the
Catnb
c/c; Col2a1-Cre mouse embryo [9,14], since ligand-indepen-
dent activation of Hedgehog (Hh) signaling in the Catnb
c/c; Col2a1-
Cre mice rescues PTHrP expression [12]. Furthermore, if Wnt/b-
catenin signaling acts by regulating PTHrP expression to control
chondrocyte hypertrophy, reduced PTHrP expression should lead
to accelerated chondrocyte hypertrophy, the opposite of the
observed phenotype for the Catnb
c/c; Col2a1-Cre mouse embryo
[9,10]. These data suggest that Wnt/b-catenin signaling regulates
chondrocyte hypertrophy independently of PTHrP expression.
The possibility remains that b-catenin interacts with PTHrP
signaling in PTHrP-responding chondrocytes. To test this, we
generated the PTHrP
2/2; Catnb
c/c; Col2a1-Cre double mutant
mouse embryos. If Wnt/b-catenin signaling acts downstream of
PTHrP signaling, initiation of chondrocyte hypertrophy should be
similarly delayed in both the Catnb
c/c; Col2a1-Cre and PTHrP
2/2;
Catnb
c/c; Col2a1-Cre embryos compared to that in the wild type
embryo. Conversely, if Wnt/b-catenin signaling acts upstream of
PTHrP signaling, initiation of chondrocyte hypertrophy should be
similarly accelerated in the PTHrP
2/2 and PTHrP
2/2; Catnb
c/c;
Col2a1-Cre embryos. Single and double mutant embryos were
harvested together with their wild type control littermates and
analyzed by skeletal preparations. The relative length of Alizarin
red stained segment (shows mineralized cells) versus Alcian blue
stained segment (shows unmineralized chondrocytes) was com-
pared in the same cartilage elements (Fig. 1B). Long bone
mineralization was increased in the PTHrP
2/2 single mutant, but
reduced in the Catnb
c/c; Col2a1-Cre and PTHrP
2/2; Catnb
c/c;
Col2a1-Cre embryos (Fig. 1B). These results suggest that final
maturation of hypertrophic chondrocytes was similarly delayed in
the Catnb
c/c; Col2a1-Cre and PTHrP
2/2; Catnb
c/c; Col2a1-Cre double
mutant embryos.
Initiation and final maturation of chondrocyte hypertrophy
were then examined more closely on histological sections of the
limb at 14.5 dpc and 16.5 dpc. In both Catnb
c/c; Col2a1-Cre and
PTHrP
2/2; Catnb
c/c; Col2a1-Cre double mutant embryos, Wnt
signaling activity was similarly reduced as shown by the reduction
in the expression of two transcriptional targets of canonical Wnt
signaling, Lef1 and Tcf1 (Fig. 1C) [15,16]. Chondrocyte hypertro-
phy was then analyzed by Safranin O staining. Hypertrophic
chondrocytes were those enlarged and lightly stained chondrocytes
whereas proliferating chondrocytes were smaller and stained
bright red. Surprisingly, although chondrocyte hypertrophy was
delayed in the Catnb
c/c; Col2a1-Cre embryo, loss of PTHrP signaling
leads to an acceleration of chondrocyte hypertrophy in the
PTHrP
2/2; Catnb
c/c; Col2a1-Cre embryo similar to that in the
PTHrP
2/2 embryo (Fig. 1D). These morphological observations
were further confirmed by molecular markers analysis. Col10a1 is
expressed in hypertrophic chondrocytes whereas Col2a1 is
expressed in proliferating chondrocytes. Col2a1 expression domain
was reduced whereas Col10a1 expression domain was expanded to
the same degree in the PTHrP
2/2 and PTHrP
2/2; Catnb
c/c;
Col2a1-Cre embryos at 14.5 dpc (Fig. 1D). Similar acceleration of
chondrocyte hypertrophy in PTHrP
2/2 and PTHrP
2/2; Catnb
c/c;
Col2a1-Cre embryos was also observed in other skeletal elements
such as the vertebral bodies (Fig. S1). These results indicate that
Wnt/b-catenin signaling is dependent on PTHrP signaling in
regulation of chondrocyte hypertrophy.
The above data suggest that active PTHrP signaling is required
for Wnt/b-catenin signaling to regulate chondrocyte hypertrophy,
but PTHrP signaling may not require b-catenin to regulate
chondrocyte hypertrophy. This predicts that in the absence of b-
catenin, PTHrP signaling levels can still determine the rate of
chondrocyte hypertrophy. To test this, we need to partially reduce
PTHrP signaling by reducing PTHrP expression. In this case, b-
catenin removal should still enhance the residual PTHrP signaling,
which will lead to a delay in chondrocyte hypertrophy. To achieve
these genetic manipulations, we partially reduced PTHrP expres-
sion by partially reducing Ihh signaling as Ihh controls PTHrP
expression. Ihh signaling was reduced by removing Smoothened
(Smo), which encodes the signaling receptor for Ihh, in the cartilage
in the Smo
c/c; Col2a1-Cre embryo [17] and Fig. 2A). PTHrP
expression was diminished in the cartilage, but still detectable in
the joint region in the Smo
c/c; Col2a1-Cre embryo (Fig. 2B).
Chondrocyte hypertrophy was accelerated in the Smo
c/c; Col2a1-
Cre embryo, as indicated by both Safranin O staining and analysis
of Col2a1 and Col10a1 expression (Fig. 2C). When b-catenin was
also removed in the Smo
c/c; Catnb
c/c; Col2a1-Cre double mutant
embryo, chondrocyte hypertrophy was delayed compared to that
in the Smo
c/c; Col2a1-Cre embryos (Fig. 2C), despite PTHrP
expression levels being similarly reduced in both (Fig. 2B). In
addition, we observed previously that when PTHrP expression was
similarly upregulated in Ptch1
c/2; Col2a1-Cre and Ptch1
c/2; Catnb
c/2;
Col2a1-Cre embryos, there was a further delay of chondrocyte
hypertrophy when b-catenin is removed [12]. Thus, in the absence
of b-catenin, PTHrP signaling still inhibits chondrocyte
hypertrophy in a dose-dependent manner, whereas in the absence
of PTHrP signaling, b-catenin has no effect on chondrocyte
hypertrophy.
Delayed chondrocyte hypertrophy can be secondary to
increased proliferation [18,19]. Interestingly, chondrocyte prolif-
eration was slightly increased in the PTHrP
2/2; Catnb
c/c; Col2a1-
Cre embryos compared to that in the PTHrP
2/2 single mutants at
16.5 dpc (Fig. S2), although chondrocyte hypertrophy was similar
in both mutants. These results indicate that Wnt/b-catenin
signaling can affect the rate at which cells divide in the
proliferating chondrocyte pool, but only PTHrP signaling controls
the brake that determines when chondrocytes exit cell cycle to
undergo hypertrophy.
Control Chondrocyte Maturation
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hypertrophic chondrocytes independently of PTHrP
signaling
In the normal process of long bone development, chondrocyte
hypertrophy is followed by hypertrophic chondrocyte maturation
to allow the invasion of osteoblasts and blood vessels. Our
observation that mineralization, but not hypertrophy, was
similarly delayed in the PTHrP
2/2; Catnb
c/c; Col2a1-Cre and
Catnb
c/c; Col2a1-Cre embryos led us to think that formation of the
early and late populations of hypertrophic chondrocytes are
differentially regulated. To test this, we further examined
chondrocyte maturation on histological sections. At 14.5 dpc,
although Col10a1 expression domains were comparable between
PTHrP
2/2 and PTHrP
2/2; Catnb
c/c; Col2a1-Cre embryos (Fig. 1D),
in stark contrast to PTHrP
2/2 embryo, where maturation of
hypertrophic chondrocytes was also accelerated, hypertrophic
chondrocyte maturation detected by von Kossa staining was
significantly delayed in the PTHrP
2/2; Catnb
c/c; Col2a1-Cre
Figure 1. Analysis of PTHrP and b-catenin mutant skeletons. (A) Sections of developing humerus at 14.5 dpc were examined by in situ
hybridization with PTHrP probes. Expression of PTHrP was reduced in periarticular chondrocytes in Catnb
c/c; Col2a1-Cre single mutant embryos
compared to that in wild type embryos. PTHrP expression was increased in the double mutant embryos compared to that in the Catnb
c/c; Col2a1-Cre
single mutant embryos. (B) Skeletal preparation of 16.5 dpc embryos. A forelimb of each embryo is shown in lower panel. Alizarin red stains the
mineralized hypertrophic chondrocytes and bone. Alcian blue stains the unmineralized cartilage. Mineralization was accelerated in the PTHrP
2/2;
Catnb
c/c; Col2a1-Cre double mutant and the PTHrP
2/2 single mutant. The bracket indicates the non-mineralized cartilage at the joint region. (C)
Consecutive sections of the radius at 14.5 dpc were examined by in situ hybridization with probes of Lef1 and Tcf1. Lef1 and Tcf1 expression were
downregulated in both Catnb
c/c; Col2a1-Cre single mutant and PTHrP
2/2; Catnb
c/c; Col2a1-Cre double mutant embryos. (D) Consecutive sections of
the developing humerus at 14.5 dpc were examined by Safranin O staining and in situ hybridization with the indicated riboprobes. Safranin O
staining and expression of Col2a1 marked nonhypertrophic chondrocytes. The nonhypertrophic domain (double headed arrow) was expanded in
Catnb
c/c; Col2a1-Cre mutant embryos whereas it was shortened to the same degree in PTHrP
2/2 single mutant and PTHrP
2/2; Catnb
c/c; Col2a1-Cre
double mutant embryos. Col10a1 expression marked hypertrophic region, which was accelerated to the same level in PTHrP
2/2 single mutant and
PTHrP
2/2; Catnb
c/c; Col2a1-Cre double mutant embryos.
doi:10.1371/journal.pone.0006067.g001
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probes specific to distinct stages of chondrocyte hypertrophy and
maturation. At 14.5 dpc, expression domains of Mmp13 and Opn
were much smaller in the PTHrP
2/2; Catnb
c/c; Col2a1-Cre embryos
compared to those in the PTHrP
2/2 embryos (Fig. 3A). By
contrast, expression domains of Ihh and Pthr1, which mark
prehypertrophic chondrocytes and early hypertrophic chondo-
cytes, were expanded in the PTHrP
2/2; Catnb
c/c; Col2a1-Cre
embryos compared to that in the PTHrP
2/2 embryos (Fig. 3B).
Thus, in the PTHrP
2/2; Catnb
c/c; Col2a1-Cre embryo, loss of
PTHrP signaling accelerated chondrocyte hypertrophy, but these
hypertrophic chondrocytes were not able to undergo further
maturation due to the blockage of Wnt/b-catenin signaling. As a
result, the Ihh and Pthr1 expressing early hypertrophic chondrocyte
population was significantly expanded. This increased Ihh
expression domain in the PTHrP
2/2; Catnb
c/c; Col2a1-Cre embryo
likely caused increased osteoblast differentiation compared to that
in the Catnb
c/c; Col2a1-Cre embryo (Fig. 3A and S3).
By 16.5 dpc, hypertrophic chondrocyte maturation, as indicat-
ed by von Kossa staining and expression of Mmp13 and Opn,
caught up in the PTHrP
2/2; Catnb
c/c; Col2a1-Cre embryos with
those in the PTHrP
2/2 embryos (Fig. 3C). However, at this stage
more Col10a1-expressing hypertrophic chondrocytes were ob-
served in the Catnb
c/c; Col2a1-Cre and PTHrP
2/2; Catnb
c/c; Col2a1-
Cre embryos compare to the wild type control and the PTHrP
2/2
embryos, respectively (Fig. 3C). This is likely due to reduced
elimination of mature hypertrophic chondrocytes caused by
delayed blood vessel invasion and bone formation when b-catenin
was removed [9]. Consistent with this, mineralized hypertrophic
chondrocytes domains were increased in both Catnb
c/c; Col2a1-Cre
and PTHrP
2/2; Catnb
c/c; Col2a1-Cre embryos compared to the wild
type control and PTHrP
2/2 embryos, respectively (Fig. 3C). In
Figure 2. Analysis of chondrocyte hypertrophy in b-catenin and Smo mutant embryos. (A) Skeletal preparation of 18.5 dpc embryos.
Mineralization (stained by Alizarin red) in the Catnb
c/c; Smo
c/c; Col2a1-Cre double mutant embryo was more advanced than that in the Catnb
c/c;
Col2a1-Cre mutant embryo, but less advanced than that in the Smo
c/c; Col2a1-Cre mutant embryo. (B) Sections of the developing distal tibia at
15.5 dpc were examined by in situ hybridization with PTHrP probes. PTHrP expression was slightly reduced only in the periarticular chondrocytes in
Catnb
c/c; Col2a1-Cre mutant embryos compared to that in wild type embryos. Catnb
c/c; Smo
c/c; Col2a1-Cre and Smo
c/c; Col2a1-Cre embryos have similar
expression of PTHrP. (C) Safranin O staining and Col10a1 expression in the developing humerus at 15.5 dpc. Non-hypertrophic chondrocyte region
(white line) was expanded in the Catnb
c/c; Col2a1-Cre mutant, but reduced in the Smo
c/c; Col2a1-Cre mutant embryo, compared that in the wild type
control. Chondrocyte hypertrophy in the Catnb
c/c; Smo
c/c; Col2a1-Cre double mutant embryo was delayed than that in the Smo
c/c; Col2a1-Cre mutant
embryo, but accelerated than that in the Catnb
c/c; Col2a1-Cre mutant embryo.
doi:10.1371/journal.pone.0006067.g002
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and chondroclasts, was delayed in both Catnb
c/c; Col2a1-Cre and
PTHrP
2/2; Catnb
c/c; Col2a1-Cre embryos compared to the wild
type control and PTHrP
2/2 embryos, respectively (Fig. 3E).
However, Vegf expression, which was detected in hypertrophic
chondrocytes was not decreased in Catnb
c/c; Col2a1-Cre and
PTHrP
2/2; Catnb
c/c; Col2a1-Cre embryos (Fig. 3E). There was also
no significant change in RANKL expression (Fig. S4). These
results suggest that delayed blood vessel invasion and trabecular
bone formation in the PTHrP
2/2; Catnb
c/c; Col2a1-Cre embryo are
Figure 3. Hypertrophic chondrocyte maturation was regulated by b-catenin independently of PTHrP. Consecutive sections of the
developing humerus at 14.5 dpc and 16.5 dpc were examined by Von Kossa staining and in situ hybridization with the indicated riboprobes. Mature
hypertrophic chondrocytes were stained black by the Von Kossa method and expressed Mmp13 and Opn. (A) Von Kossa staining and Mmp13 and Opn
expression were much reduced in both Catnb
c/c; Col2a1-Cre and PTHrP
2/2; Catnb
c/c; Col2a1-Cre mutant embryos at 14.5 dpc. (B) Ihh and Pthr1 were
expressed in the less mature hypertrophic chondrocytes (double-headed arrow). This domain was expanded significantly only in the PTHrP
2/2;
Catnb
c/c; Col2a1-Cre mutant embryos at 14.5 dpc. (C) At 16.5 dpc, chondrocyte final maturation in the Catnb
c/c; Col2a1-Cre and PTHrP
2/2; Catnb
c/c;
Col2a1-Cre mutant was similar to that of the wild type control and PTHrP
2/2 mutant, respectively. (D) Expansion of Ihh and Pthr1 expression domains
(white line) were still observed in the PTHrP
2/2; Catnb
c/c; Col2a1-Cre mutant at 16.5 dpc. (E) Expression of Mmp9 and Vegf in the developing humerus
of the indicated genotypes at 14.5 dpc.
doi:10.1371/journal.pone.0006067.g003
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RANKL. Interestingly, domains of Ihh/Pthr1 expressing- early
hypertrophic chondrocytes were still expanded in the PTHrP
2/2;
Catnb
c/c; Col2a1-Cre embryos at 16.5 dpc, particularly in the
periphery of the cartilage compared to that in the PTHrP
2/2
embryos (Fig. 3D), which created a zone with a mixture of early
and late mature hypertrophic chondrocytes. Taken together, these
results indicate that the Wnt/b-catenin pathway regulates
hypertrophic chondrocyte final maturation, at least partly and
transiently, in a manner independent of PTHrP signaling.
Wnt signaling may regulate chondrocyte hypertrophy
and maturation non-cell autonomously
As PTHrP signaling controls chondrocyte hypertrophy cell
autonomously [23], we tested whether the Wnt/b-catenin
signaling pathway also acts cell autonomously. We expressed an
activated form of b-catenin in subsets of chondrocytes using a
mouse line with the exon 3 of b-catenin floxed (Catnb
Ex3) [24]. This
mouse line was crossed with a tamoxifen (TM) inducible Cre line,
Col2a1-CreER [25]. As the tamoxifen induced Cre activity is not
robust in all cells, the activated form of b-catenin is only expressed
in a subset of chondrocytes in the Catnb
Ex3/+; Col2a1-CreER
embryos following TM injection. Since Lef1 is a transcription
target of Wnt/b-catenin signaling [16], in these subset of
chondrocytes, Lef1 expression was upregulated (Fig. 4A). In
addition, bone formation was increased in the TM injected
Catnb
Ex3/+; Col2a1-CreER embryos indicated by von Kossa staining
(Fig. 4A), suggesting that Wnt/ b-catenin signaling in chondro-
cytes may also promote bone formation in the perichondrium non-
cell autonomously. Interestingly, Safranin O staining and Col2a1
expression was significantly downregulated in the chondrocytes
that expressed the activated form of b-catenin (Fig. 4A). However,
these cells did not ectopically express Col10a1, a marker for
hypertrophic chondrocytes (Fig. 4A). This is in sharp contrast to
the normal process of chondrocyte hypertrophy in which Col2a1
expression is turned off, while Col10a1 expression is switched on.
This is also drastically different from the Pthr1
2/2 clones in
cartilage [23], in which loss of PTHrP signaling led to cell
autonomous expression of Col10a1. In addition, while PTHrP
signaling does not affect the determination of chondrocyte lineage
[26,27], activated Wnt signaling in the developing cartilage can
change chondrocyte identity to the ones that resemble cells found
in the joint interzone or joint [28]. These data suggest that
activated b-catenin signaling acts cell autonomously to control
chondrocyte identity, but non-cell autonomously in regulating
chondrocyte hypertrophy. Among the secreted signaling molecules
that can regulate chondrocyte hypertrophy, Growth differentiation
factor 5 (Gdf5) and Bmp2 expression are upregulated by Wnt/b-
catenin signaling [28–30]. To address the potential role of these
genes, we examined Bmp signaling activities in our mutant mice
(Fig. 4B). In and around chondrocytes that express activated b-
catenin, we observed stronger phosphorylation of Smad1, 5 and 8,
indicating increased Bmp signaling [31]. As Bmp/Gdf5 signaling
has been shown to promote chondrocyte hypertrophy [32–34],
Gdf5 and Bmp2 are likely to participate in mediating the non-cell
autonomous function of Wnt/b-catenin signaling in chondrocyte
hypertrophy.
Discussion
We report here that during mouse embryonic cartilage
development, Wnt/b-catenin signaling controls chondrocyte
hypertrophy and final maturation by two distinct mechanisms.
Wnt/b-catenin signaling regulates initiation of chondrocyte
hypertrophy by antagonizing PTHrP signaling, whereas it acts
independently of PTHrP signaling in controlling the final
maturation of hypertrophic chondrocytes (Fig. 4C). Our results
indicate that chondrocyte hypertrophy and final maturation are
two separate developmental events that are regulated by distinct
signaling interactions.
Our data suggests that delayed chondrocyte hypertrophy in the
Catnb
c/c; Col2a1-Cre mutant embryo is due to upregulated PTHrP
signaling, not enhanced PTHrP expression. As b-catenin is
required for activating the expression of downstream targets of
the canonical Wnt signaling pathway, a possible scenario is that
one of the transcription targets of the canonical Wnt signaling
pathway in the chondrocytes suppresses the PTHrP signaling
activity. Alternatively, the b-catenin protein may directly suppress
PTHrP signaling activity by interacting with PTHrP signaling
components. Interaction of b-catenin with components of other
signaling pathways may be an important mechanism underlying
Wnt signaling cross regulation with other pathways. For instance,
a LEF/TCF independent regulatory role of b-catenin in cell
lineage determination has been demonstrated during pituitary
gland development, in which b-catenin binds a specific homeo-
domain factor, Prop1, to activate expression of the critical lineage-
determining transcription factor, Pit1 [35]. However, if b-catenin
inhibits PTHrP signaling by directly binding PTHrP signaling
component(s), one may predict that PTHrP receptor and activated
b-catenin both play a cell-autonomous role in chondrocyte
hypertrophy. Although the PTHrP receptor acts cell autonomous-
ly in regulating chondrocyte hypertrophy [23], ectopic chondro-
cyte hypertrophy is not detected in chondrocytes expressing
activated b-catenin as these cells have lost their chondrocyte
identity because they express neither Col2a1 nor Col10a1.
Interestingly, PTH activation of Pthr1 has been shown to activate
the Wnt/b-catenin signaling directly by stabilizing b-catenin
protein in osteoblasts [36]. However, in chondrocytes, it is unlikely
that PTH/PTHrP signaling regulates chondrocyte hypertrophy
through b-catenin as loss of PTH/PTHrP and Wnt/b-catenin
signaling leads to opposite phenotypes.
Wnt/b-catenin signaling has two distinct roles in cartilage
development. First, it inhibits chondrocyte cell lineage determi-
nation and maintenance [28]. Second, it promotes chondrocyte
hypertrophy by inhibiting PTHrP signaling. However, such
inhibition is likely to be incomplete. In addition, Wnt/b-catenin
signaling may exert distinct functions in a dose dependent manner.
It is conceivable that the two functions of Wnt/b-catenin signaling
are also dose-dependent: Strong Wnt/b-catenin signaling (i.e.,
expression of activated b-catenin) inhibits chondrocyte cell fate
determination and maintenance whereas weaker Wnt/b-catenin
signaling promotes chondrocyte hypertrophy by reducing PTHrP
signaling activities. Our results suggest that Wnt/b-catenin
signaling may also interact with PTHrP signaling indirectly
through a secondary signaling pathway. To this end, it will be
interesting to further investigate genetically whether Gdf5/Bmp
signaling control initiation chondrocyte hypertrophy by antago-
nizing PTHrP signaling and whether Gdf5/Bmp signaling also
mediates the role of Wnt/b-catenin signaling in hypertrophic
chondrocyte maturation.
Materials and Methods
Mice generation and Genotyping
Embryos were generated by crosses between mice carrying
heterozygous PTHrP null allele PTHrP
+/2 [26], b-catenin condi-
tional allele Catnb
c/c or gain-of-function allele Catnb
ex3, and a
transgene Cre which is under the regulation of Col2a1 promoter
Control Chondrocyte Maturation
PLoS ONE | www.plosone.org 6 June 2009 | Volume 4 | Issue 6 | e6067Figure 4. b-catenin may control chondrocyte hypertrophy non-cell autonomously. Tamoxifen was injected into pregnant females at
13.5 dpc. Embryos were harvested at 17.5 dpc and sections of the proximal tibia were analyzed by Safranin O staining, in situ hybridization with the
indicated probes and immnohistochemistry. (A) Upregulated Wnt/b-catenin signaling was indicated by ectopic Lef1 expression and loss of Safranin O
staining and Col2a1 expression (arrow). Pictures of higher magnification of the boxed area are shown as insets. Col10a1 expression was not
ectopically detected in chondrocytes that had lost Col2a1 expression. (B) Increased p-Smad1/5/8 staining (red) was observed in chondrocyte patches
of Catnb
ex3/+; Col2a1-CreER mouse embryos. Such increase in p-Smad1/5/8 staining was in the area with increased b-catenin staining (green). But p-
Smad1/5/8 and b-catenin staining did not colocalize in many chondrocytes. Some cells with increased p-Smad1/5/8 staining (arrows) did not show
increased b-catenin staining. (C) Distinct genetic interactions between Wnt/b-catenin and PTHrP signaling in regulating chondrocyte hypertrophy
and maturation. The sequential process of chondrocyte hypertrophy and maturation in developing wild type and indicated mutant long bone
cartilage were shown in the diagram in the upper panel. Hypertrophic chondrocytes are enlarged and undergo final maturation before they are
replaced by the trabecular bone. Initiation of chondrocyte hypertrophy and final maturation are two separate processes that are differentially
regulated by Wnt/b-catenin and PTHrP signaling. Wnt/b-catenin signaling controls chondrocyte hypertrophy by inhibiting PTHrP signaling activity.
However, Wnt/b-catenin signaling promoted final maturation of hypertrophic chondrocyte independently of PTHrP signaling.
doi:10.1371/journal.pone.0006067.g004
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PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e6067and enhancer. Embryos were collected at 14.5, 15.5 and 16.5 dpc
and embryos were analyzed as described. Genotyping for the
Col2a1-Cre transgene and b-catenin alleles were performed as
previously described [9].
Skeletal Preparation
Alizarin red and Alcian blue staining of skeletons was conducted
as previously described [12]. Embryos were eviscated, fixed for
48 hours in ethanol and then transferred to acetone for 24 hours.
Embryos were stained overnight at 37uC followed by 2 additional
days at room temperature. Then embryos were cleared in 1%
KOH and stored in 80% glycerol.
Histology and in situ Hybridization
Limbs were fixed by 4% paraformaldehyde at 4uC overnight,
embedded in paraffin and sectioned at 6 mm. Sections were stained
by Safranin O and Von Kossa method. In situ hybridization was
performed as previously described [8].
35S-lablled riboprobes of Col
2a1, Col 10a1, Ihh, Pthr1, PTHrP, Opn, Mmp13, Mmp9 and Vegf were
synthesized as previously [9,12] and applied to limb sections. For
immunnohistochemistry, primary antibodies used include anti b-
catenin mouse monoclonal IgG (Transduction Lab) at 1:50, anti-
phospho-Smad1/5/8 rabbit polyclonal IgG (Cell signaling) at 1:100
and anti-RANKL mouse monoclonal IgG (IMGENEX) at 1:50.
The signal was detected using FITC-conjugated secondary
antibodies (Molecular Probes) or ABC kits (Vector Laboratories).
Tamoxifen preparation and injection
60 mg/ml Tamoxifen (Sigma) was dissolved in corn oil (Sigma)
and sonicated until the solution became clear. The solution was
filtered and 0.05 ml was injected intraperitoneally into the
pregnant female mice at 13.5 dpc and the embryos were harvested
at 17.5 dpc.
Supporting Information
Figure S1 Analysis of chondrocyte hypertrophy in vertebral
skeletons. Vertebral skeletons were visualized by Alcian Blue /
Alizarin Red staining at E14.5. Mineralization was greatly reduced
in the ribs and vertebral bodies in both the Catnbc/c; Col2a1-Cre
single mutant and the PTHrP2/2; Catnbc/c; Col2a1-Cre double
mutant. Chondrocyte hypertrophy was revealed by Safranin O
staining and the expression of Col2a1 and Col10a1 in sections of
vertebral bodies at E14.5. Compared to the Catnbc/c; Col2a1-
Cre single mutant, chondrocyte hypertrophy in the PTHrP2/2;
Catnbc/c; Col2a1-Cre double mutant was much accelerated and
similar to that in PTHrP2/2 single mutant embryos indicated by
the expression of Col10a1.
Found at: doi:10.1371/journal.pone.0006067.s001 (3.47 MB TIF)
Figure S2 Analysis of chondrocyte proliferation in PTHrP and
b-catenin mutant embryos. (A) BrdU-labeled chondrocytes were
detected by immunohistochemistry on sections of distal tibia at
16.5dpc. Zone I cells are resting chondrocytes and Zone II are
columnary proliferating chondrocytes. Zone I and II were greatly
reduced and the difference between them was not clear in the
PTHrP2/2 single mutant and PTHrP2/2; Catnbc/c; Col2a1-
Cre double mutant embryos. The entire proliferating region was
marked as Zone I and II. (B) The percentage of BrdU labeled
chondrocytes was counted from four different samples of each
genotype and the average with standard deviations are shown.
Significant difference with p,0.05 is shown.
Found at: doi:10.1371/journal.pone.0006067.s002 (2.47 MB TIF)
Figure S3 Analysis of osteoblast differentiation in PTHrP and b-
catenin mutant embryos. Consecutive sections of developing
humerus at E14.5 and E16.5 were examined by in situ
hybridization with indicated probes. (A) At E14.5, expression of
early osteoblast marker Runx2 and Osx in PTHrP2/2; Catnbc/
c; Col2a1-Cre double mutant embryos was accelerated to the
same level as that in PTHrP2/2 mutant embryos. (B) At E16.5,
expression of Runx2 and Osx in double mutant embryos was
accelerated whereas Osc expression was still delayed compared to
that in PTHrP2/2 single mutant embryos.
Found at: doi:10.1371/journal.pone.0006067.s003 (4.01 MB TIF)
Figure S4 Analysis of RANKL expression in PTHrP and b-
catenin mutant embryos. Proximal tibia sections at E16.5 were
examined by immunohistochemistry with a RANKL monoclonal
antibody. The expression of RANKL by osteoblasts is indicated by
an arrow. RANKL expression in mature hypertrophic chondro-
cytes was very low and slightly increased in the Catnbc/c; Col2a1-
Cre mutant but not in the PTHrP2/2 and PTHrP2/2;Catnbc/
c;Col2a1-Cre mutant embryos.
Found at: doi:10.1371/journal.pone.0006067.s004 (3.75 MB TIF)
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